Table 5.
Cardiomyopathy and triheptanoin treatment
| Patient ID (Current Age) |
Diagnosis | Participated in Retrospective Study |
Ejection Fraction Pretreatment (%) |
Ejection Fraction Post treatment (%) |
|---|---|---|---|---|
| 3 (6 yrs) | CACT | Y | 35 | 67 |
| 7 (8 yrs) | LCHAD | Y | 37 | “Normal” |
| 11 (9 yrs) | CPT2 | Y | 31 | Transplanted |
| 13 (12 yrs) | VLCAD | Y | 40 | 61 |
| 15 (19 yrs)* | VLCAD | N | Resolved before C7 | |
| 19 (23 yrs)* | VLCAD | Y | Resolved before C7 | |
| 21 (18 yrs)* | VLCAD | N | Persistent cardiomyopathy | Resolved |
| 24 (3 yrs) | VLCAD | Y | 65 | 63 |
| 25 (11 yrs) | VLCAD | N | 59 | 52 |
| 26 (3 yrs) | VLCAD | N | “Very low” | 71 |
| 28 (34 yrs) | VLCAD | N | 35 | 35 |
| 29 (2 yrs) | VLCAD | N | 44 | 46–53 |
| 32 (35 yrs) | TFP | N | 45 | 50–55 |
| 33 (18 mths) | LCHAD | N | 22 | 56 |
C7=triheptanoin
*
Results for these patients are also included in [9]. Patient 21 withdrew from triheptanoin therapy at age 18 yrs.